News

Apellis Pharmaceuticals to Discuss Q2 2025 Results in Call

Apellis Pharmaceuticals to Discuss Q2 2025 Results in Call

Apellis Pharmaceuticals to Host Conference Call on Upcoming Financial Results

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a pioneering biopharmaceutical company, is gearing up for an important conference call set for July 31, 2025. This call will discuss the company’s financial results for the second quarter of the year.

Details of the Financial Call

The conference call is scheduled to begin at 8:30 a.m. Eastern Time. Investors and interested parties are encouraged to pre-register for the call to ensure smooth communication during the event. Accessing the live audio webcast will also be available on Apellis’ official website, under the 'Events and Presentations' section.

Following the live call, Apellis plans to provide a replay of the webcast that will be available for 90 days. This makes it easier for those who cannot attend the live session to stay informed about the company's financial health and strategic direction.

About Apellis Pharmaceuticals

Founded with a mission to innovate, Apellis Pharmaceuticals has emerged as a leader in biopharmaceutical science. The company focuses on the development of therapeutics aimed at unmet medical needs, particularly in the field of complement-related diseases. Recently, Apellis has successfully introduced two groundbreaking medications targeting C3, marking a significant advancement in treatment options for serious conditions.

First-of-Its-Kind Therapies

Among their achievements, Apellis launched the first-ever therapy for geographic atrophy, a condition known to lead to blindness. This innovative approach is part of a broader vision to harness the power of targeting the complement system to address various serious diseases.

Commitment to Innovation

Apellis Pharmaceuticals believes that they have only scratched the surface of what can be achieved through complement modulation. The company is dedicated to exploring new frontiers in medicine that could revolutionize treatment protocols for numerous challenging conditions.

Staying Connected with Apellis

For ongoing information about Apellis and its developments, the company encourages stakeholders to visit their website and follow their social media profiles on platforms such as Twitter and LinkedIn. This is a great way for both patients and investors to stay updated on future outcomes and announcements.

Investor Relations

Investors can connect directly with Apellis through their dedicated investor relations contact, Neil Carnahan, who is available at neil.carnahan@apellis.com or by phone at 617.977.5703. They are always open to inquiries and provide support to stakeholders interested in the company's performance and trajectory.

Frequently Asked Questions

What is Apellis Pharmaceuticals focusing on in their upcoming call?

They will discuss their financial results for the second quarter of 2025 as well as strategic insights moving forward.

How can I join the conference call?

You can pre-register for the call through their website to gain access to the live session.

Will there be a replay available after the conference call?

Yes, a replay of the webcast will be available for 90 days after the event for those who want to catch up.

What makes Apellis' therapies notable?

They are the first approved medicines targeting C3 in the complement system, specifically for treating conditions like geographic atrophy.

Who can I contact for investor inquiries?

Neil Carnahan is available for any investor-related queries via email at neil.carnahan@apellis.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
SM's PHP70 Billion Profit Shows a Balanced Growth Engine

Updated Category News Views 43

PHP70.2 billion in nine-month profit is not the sort of number that needs a brass band; it needs a closer look at the machinery underneath. SM Investments grew consolidated net income 9% from PHP64.4 billion a year earlier, while revenue rose a more modest 5% to PHP506.8 billion. That spread is encouraging, but it also tells investors not to lazily call this a one-speed...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 125

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 51

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 55

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading

Top 5 Most Recently Viewed Articles

NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale

Updated Category News Views 195

NANO Nuclear Energy Partners with Cambridge Atom Works for ODIN Sale NANO Nuclear Energy Inc. has made a pivotal move by signing a letter of intent to sell its innovative ODIN™ low-pressure coolant reactor technology. This strategic decision not only signifies NANO Nuclear's commitment to optimizing their technology portfolio but also enables a sharper focus on their...

Continue Reading
Project C.U.R.E. and Microsoft: Transforming Global Health Access

Updated Category News Views 244

Transforming Global Healthcare Through Innovative Partnerships In a world where access to essential healthcare is still a significant challenge, Project C.U.R.E. has teamed up with Microsoft to make a meaningful difference. This collaboration aims to change the lives of millions by providing vital medical resources to underserved populations. With over 4.5 billion people...

Continue Reading
How STRADVISION Is Leading the Charge in Automotive Innovation

Updated Category News Views 395

Transforming the Automotive Industry: STRADVISION's Role STRADVISION, a pioneer in deep learning-based vision perception technology, is at the forefront of a revolution in the automotive industry. Their latest edition of the STRADVISION Market Intelligence Report delves into significant trends transforming the automotive landscape, influenced by advancements in autonomous...

Continue Reading
Holdings and Legal Developments: Atkore Inc. Class Action Insight

Updated Category News Views 182

Understanding the Atkore Inc. Class Action Lawsuit In recent developments, Atkore Inc. (NASDAQ: ATKR) is facing a class action lawsuit that has raised significant attention among investors. The lawsuit, officially titled Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v. Atkore Inc., highlights serious allegations against the company and its...

Continue Reading
Brenda Snow's Empowering New Book for Patients on Health Journey

Updated Category News Views 279

Brenda Snow's Inspiring Book on Navigating Health Challenges Brenda Snow's upcoming book is generating buzz as a vital resource for individuals grappling with serious health issues. This essential guide, titled Diagnosed: The Essential Guide to Navigating the Patient's Journey, is set to empower patients and caregivers alike. A Personal Narrative That Inspires In her...

Continue Reading